Convalescent plasma given to hospitalized COVID-19 patients did not improve survival or rates of release from the hospital within 28 days, need for invasive mechanical ventilation, or death, according to the most recent findings of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial in the United Kingdom.The results, published late last week in The Lancet, add to evidence that SARS-CoV-2 antibody-rich plasma taken from COVID-19 survivors doesn't benefit severely ill coronavirus patients.
The RECOVERY trial is evaluating several possible treatments for hospitalized COVID-19 patients at 177 National Health Services sites.Death, mechanical ventilation, hospital releaseThe researchers assigned 11,558 patients to receive either